REG - IP Group PLC - Director Declaration

IPAnnouncement

13/05/2022 12:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220513:nRSM4816La&default-theme=true

RNS Number : 4816L  IP Group PLC  13 May 2022

 FOR RELEASE ON  13 May 2022

 

Director Declaration

IP Group plc (LSE: IPO) ("the Group"), which develops world-changing science
and technology businesses across life sciences, technology and cleantech,
confirms that Elaine Sullivan, a non-executive director of the Group, has been
appointed as a director of Nykode Therapeutics AS. This disclosure is made in
accordance with LR 9.6.14R of the Listing Rules.

 

For more information, please contact:

 

 IP Group plc                                              www.ipgroupplc.com (http://www.ipgroupplc.com)
 Angela Leach, Company Secretary                           +44 (0) 20 7444 0050

Liz Vaughan-Adams, Communications
+44 (0) 20 7444 0062/+44 (0) 7979 853802

 

Notes for editors

 

About IP Group

 

IP Group develops world-changing science and technology businesses across life
sciences, technology and cleantech. The Group has a strong track record of
success, having been the founder investor in a number of high-profile
companies including Oxford Nanopore Technologies plc, and has one of the most
exciting portfolios of high-growth businesses in Europe. The Group also owns
Parkwalk, the UK's largest growth EIS fund manager which backs world-changing
technologies emerging from the UK's leading universities and research
institutions. IP Group is listed on the Main Market of the London Stock
Exchange under the code IPO.

For more information, please visit our website at www.ipgroupplc.com
(http://www.ipgroupplc.com) .

ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RDNBKNBQDBKDDPD